# Deuteration may reduce the efficacy of dextromethorphan in treating agitation in Alzheimer’s disease

**Authors:** Anton Bespalov, Jina Swartz, Nadine Knowles, Hans J. Moebius

PMC · DOI: 10.1186/s13195-025-01780-0 · 2025-06-09

## TL;DR

Deuteration in a drug combination may reduce its effectiveness in treating Alzheimer's-related agitation.

## Contribution

Shows that deuteration may negatively affect the drug's action at specific brain receptors.

## Key findings

- Deuteration increased IC50 for dextrorphan 16-fold at NR2D-containing NMDA receptors.
- Deuteration increased IC50 for dextromethorphan about two-fold at the same receptors.
- Clinical failures of AVP-786 may be due to deuteration's impact on pharmacodynamics.

## Abstract

Agitation is one of the most prevalent neuropsychiatric symptoms leading to institutionalization in individuals with Alzheimer’s disease (AD) dementia. It is associated with poor outcomes, including reduced functional ability, reduced quality of life, accelerated disease progression, increased mortality, and significant economic burden. Following an initial report demonstrating the strong efficacy of a combination of dextromethorphan and the CYP2D6 inhibitor quinidine, several follow-up development efforts have explored this approach. Axsome Therapeutics has reported positive results in three out of four clinical trials evaluating AXS-05, a combination of dextromethorphan with another CYP2D6 inhibitor, bupropion. In contrast, Otsuka’s AVP-786, a combination of deuterated dextromethorphan and quinidine, has yielded predominantly negative results. It is widely believed that deuteration alters a molecule’s pharmacokinetic properties without affecting its pharmacodynamics. However, in our patch-clamp experiments, deuteration resulted in a 16-fold increase in IC50 for dextrorphan and about two-fold increase for dextromethorphan at NMDA receptors containing the NR2D subunit. Thus, based on both clinical data and emerging pharmacological evidence, we hypothesize that AVP-786 failed to demonstrate efficacy in treating agitation in AD dementia due to the negative impact of deuteration on dextromethorphan’s pharmacodynamic properties.

## Linked entities

- **Proteins:** GRIN2D (glutamate ionotropic receptor NMDA type subunit 2D)
- **Chemicals:** dextromethorphan (PubChem CID 5360696), quinidine (PubChem CID 101744), bupropion (PubChem CID 444), dextrorphan (PubChem CID 5360697)
- **Diseases:** Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)) [NCBI Gene 1565] {aka CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2}, GRIN2D (glutamate ionotropic receptor NMDA type subunit 2D) [NCBI Gene 2906] {aka DEE46, EB11, EIEE46, GluN2D, NMDAR2D, NR2D}
- **Diseases:** dementia (MESH:D003704), neuropsychiatric symptoms (MESH:D001523), Agitation (MESH:D011595), AD (MESH:D000544)
- **Chemicals:** AXS (MESH:D000658), AVP-786 (-), quinidine (MESH:D011802), dextrorphan (MESH:D003917), dextromethorphan (MESH:D003915), bupropion (MESH:D016642)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12147264/full.md

---
Source: https://tomesphere.com/paper/PMC12147264